Premium
Elderfield pyrimidine mustard in chronic lymphocytic leukemia
Author(s) -
Louis John,
Wright Thomas L.,
Dessel Bert H.,
Wilson Henry E.,
Louis Nicholas B.
Publication year - 1970
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1970114513
Subject(s) - medicine , antacid , chronic lymphocytic leukemia , leukemia , bone marrow , gastroenterology
Eighty patients with chronic lymphocytic leukemia received one of 4 doses of elderfield pyrimidine mustard (EPM) orally with an antacid. Complete remissions were induced in 7 (8.7 per cent), whereas 31 others (38 per cent) developed remissions of lesser degree. The lymphocyte counts decreased to normal levels in 38 (47.5 per cent). In 26 patients (32.5 per cent) the differential leukocyte count became normal. Bone marrow suppression and gastroenteropathy were the principle toxic manifestations; these subsided promptly when EPM was discontinued. The optimum divided daily dose of EPM appears to be 0.25 mg. per kilogram.